#Spain #Barcelona #pharmaceutical #CDMO #ESTEVE

ESTEVE's Ambitious Growth and Expansion

ESTEVE, a prominent player in the pharmaceutical industry, has recently unveiled its impressive results for 2025, showcasing a robust transformation into a global healthcare entity through strategic expansion and commitment to sustainability.

Significant Growth in Financials

In 2025, ESTEVE reported a remarkable double-digit growth, achieving a 14% increase in net revenues compared to 2024, reaching €828 million. EBITDA also surged by 19%, totaling €151 million. This growth is attributed to novel assets added in both their pharmaceutical and Contract Development and Manufacturing Organization (CDMO) sectors, underscoring the company’s strategic focus.

Strategic Acquisitions and Portfolio Expansion

Over the past 18 months, ESTEVE has bolstered its pharmaceutical portfolio by integrating eight new products through targeted acquisitions. The company successfully completed the acquisition of TerSera's Infusion Business Unit, which includes two high-specialization drugs, further strengthening their offerings. This acquisition aligns with their efforts to cater to underserved patient groups in oncology and endocrinology.

Simultaneously, their CDMO operations have witnessed substantial growth through the acquisition of Regis Technologies in the United States. This bolstered ESTEVE’s capabilities in early drug development, aiding in their mission to support partners throughout the entire value chain—from early development to commercial manufacturing.

Commitment to ESG and Social Responsibility

In a landmark achievement, ESTEVE secured B-Corp certification, recognizing its dedication to high international standards concerning social, environmental performance, transparency, and accountability. Their sustainability strategies are deeply integrated into the company’s governance, focusing on minimizing ecological and social footprints. Through ongoing investments in renewable energy and efficient waste management, ESTEVE demonstrates its commitment to sustainable practices.

Moreover, ESTEVE has significantly enhanced its community engagement by supporting patient organizations and health facilities, positively impacting thousands globally.

Future Outlook and Continuous Investment

Looking ahead, ESTEVE aims to achieve a net revenue of €1 billion by 2027, driven by both organic and inorganic growth within the pharmaceutical and CDMO sectors. In 2025 alone, the company invested €49 million into product and process development, a 7% increase from the previous year, while capital expenditures amounted to €104 million, primarily for new industrial site construction.

The cumulative investment over the past two years has exceeded €500 million, directed towards developing high-specialized treatment options and augmenting CDMO services.

Conclusion

Through strategic acquisitions, a commitment to social responsibility, and robust financial growth, ESTEVE is not merely expanding—it is setting new standards in the global healthcare landscape. The organization’s strong focus on sustainability and its commitment to meeting the needs of complex patients positions it as a formidable leader in the international healthcare industry. As they continue to innovate and grow, ESTEVE will undeniably play a crucial role in the future of healthcare around the world.

For further information about ESTEVE's strategic initiatives and their impact on the healthcare industry, visit www.esteve.com.